39669
document
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ( ONTARGET ) : implications for reduced cardiovascular risk . The recently published Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ( ONTARGET ) in patients with vascular disease or high-risk diabetes , as the largest published comparative trial of these agent classes , provides further evidence concerning the comparison between the angiotensin-receptor blockers ( ARBs ) and the angiotensin-converting enzyme inhibitors ( ACEIs ) . In this trial , telmisartan ( an ARB ) was non-inferior to ramipril ( an ACEI ) in reducing fatal and nonfatal cardiovascular events . Moreover , ONTARGET is an example of a high-quality noninferiority trial . However , the combination of the 2 agents was associated with more adverse effects without an increase in benefit . The study differed from several other comparative studies in which the dose and choice of ACEI was left to individual physicians . Further , in ONTARGET , the ACEI was not titrated to the maximum dose and patients with heart failure were excluded .
39670
Intervention_Pharmacological
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ( ONTARGET ) :
39671
Intervention_Pharmacological
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial ( ONTARGET )
39672
Intervention_Pharmacological
angiotensin-receptor blockers ( ARBs )
39673
Intervention_Pharmacological
angiotensin-converting enzyme inhibitors ( ACEIs ) .
39674
Intervention_Pharmacological
telmisartan ( an ARB )
39675
Intervention_Pharmacological
ramipril ( an ACEI )
39676
Intervention_Physical
ONTARGET
39677
Intervention_Physical
ACEI
39678
Intervention_Pharmacological
ONTARGET
39679
Intervention_Pharmacological
ACEI
39680
Outcome_Physical
cardiovascular risk
39681
Outcome_Physical
fatal and nonfatal cardiovascular events
39682
Outcome_Adverse-effects
adverse effects
39683
Participant_Condition
patients with vascular disease or high-risk diabetes